ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > How much higher can PMN go?

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Oct 12, 2021 6:24pm

175 Views

Post# 33999052

RE:RE:How much higher can PMN go?

I wouldn't put much stock on that Nasdaq move. It's a wish that many companies have , it's not guaranteed that it will happen or that the SP will hold or appreciate its value.I know of plenty of companies that regretted that move.. I think with some good NRs over the next few months the SP will likely rise and may make RS split less painful ..today PMN close to a 1 million shares on the bid @.18 , are the trying to stop the slide or to force the buying above ? We will see soon enough...